Core One through its network of clinics has access to databases comprising over 275,000 patients and will endeavour to roll out its portfolio of psychedelic formulations, including Vocan’s optimized biosynthetic psilocybin, and Akome’s neurological disease candidate drugs once legislation allows, and upon final development.
Medical Clinics
